Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921468 | 0.92 | HTR6 (0.37) | HTR6KDM4EKMT2ANPSR1SIGMAR1 | |
| SCHEMBL14729245 | 0.92 | HTR6 (0.37) | HTR6KDM4EKMT2ANPSR1SIGMAR1 | |
| SCHEMBL6921536 | 0.92 | HTR6 (0.37) | HTR6KDM4EKMT2ANPSR1SIGMAR1 | |
| SCHEMBL15132954 | 0.83 | HTR6 (0.35) | HTR6PTGDR2KDM4EKMT2ANPSR1 | |
| SCHEMBL14729240 | 0.82 | HTR6 (0.38) | HTR6KDM4EKMT2ANPSR1SIGMAR1 | |
| SCHEMBL6921538 | 0.82 | HTR6 (0.40) | HTR6PTGDR2KDM4EKMT2ANPSR1 | |
| SCHEMBL14729237 | 0.82 | HTR6 (0.41) | HTR6PTGDR2KDM4EKMT2ANPSR1 | |
| SCHEMBL13834659 | 0.81 | HTR6 (0.39) | HTR6PTGDR2SIGMAR1 | |
| SCHEMBL13834455 | 0.80 | HTR6 (0.43) | HTR6PTGDR2KMT2ASIGMAR1CYP2C9 | |
| SCHEMBL14729242 | 0.79 | HTR6 (0.38) | HTR6KDM4EKMT2ANPSR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2011038164-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HTR6 47/4885PTGDR2 80/4885KDM4E 2111/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HTR6 88/4885PTGDR2 30/4885KDM4E 2173/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | HTR6 22/4885PTGDR2 114/4885KDM4E 2470/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HTR6 47/4885PTGDR2 80/4885KDM4E 2111/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HTR6 85/4885PTGDR2 30/4885KDM4E 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.